

(19) World Intellectual Property
Organization
International Bureau



(43) International Publication Date
9 June 2005 (09.06.2005)

PCT

(10) International Publication Number
WO 2005/052184 A1

(51) International Patent Classification?:
G01N 33/574, A61K 47/42

C12Q 1/04,

(71) Applicants and

(72) Inventors: **PARISSENTI, Amadeo** [CA/CA]; c/o Northeastern Regional Cancer Centre, 41 Ramsey Lake Road, Sudbury, Ontario P3E 5J1 (CA). **GUO, Baoqing** [CA/CA]; c/o Northeastern Ontario Regional Cancer Centre, 41 Ramsey Lake Road, Sudbury, Ontario P3E 5J1 (CA). **VILLENEUVE, David, J.** [CA/CA]; c/o Northeastern Ontario Regional Cancer Centre, 41 Ramsey Lake Road, Sudbury, Ontario P3E 5J1 (CA). **HEMBRUFF, Stacey, L.** [CA/CA]; c/o Northeastern Ontario Regional Cancer Centre, 41 Ramsey Lake Road, Sudbury, Ontario P3E 5J1 (CA).

(21) International Application Number:

PCT/CA2004/002039

(22) International Filing Date:

26 November 2004 (26.11.2004)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:


60/525,479 26 November 2003 (26.11.2003) US

(74) Agent: **RIDOUT & MAYBEE LLP**; 19th Floor, 150 Metcalfe Street, Ottawa, Ontario K2P 1P1 (CA).

(81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

[Continued on next page]

(54) Title: USE OF ISOGENIC DRUG-RESISTANT CELL LINES TO DETERMINE THE SEQUENCE OF CHEMOTHERAPEUTIC DRUG TREATMENT



(57) Abstract: The present invention provides isogenic cell lines and uses said isogenic cell lines in a method for determining a sequence to administer multiple types of chemotherapeutic drugs for killing cancerous cells to reduce the induction of drug cross-resistance in a patient. The methods also involves screening drug candidates to select a lead anticancer drug from amongst a plurality of candidate drugs, the lead having a reduced capacity to induce cross resistance in a patient against one or more known anticancer drugs, and all of the drugs having the ability to kill cancerous cells of the same selected tumour type. Moreover, the methods involve determining a sequence to administer multiple types of cytotoxic drugs for killing undesired cells to reduce the indication of drug cross-resistance in the cells.



WO 2005/052184 A1



(84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

Published:

— with international search report